DeepLook

New Haven biotech DeepLook Medical’s AI-driven imaging software targets better breast cancer detection

Antonette Ho2024-11-29T16:54:02-05:00Enter New Haven-based medical technology startup DeepLook Medical. Since its founding in December 2018, DeepLook, based at 470 James St., has developed and secured two patents and FDA clearance for its medical imaging analysis software, called DL Precise. The company, which has raised millions of dollars in venture funding, says its shape-recognition software significantly improves the accuracy and efficiency of medical imaging, and is specifically designed to detect cancer in dense breast tissue. When it was granted its second patent...

DeepLook Medical: Medical Imaging Company Raises Series A

Antonette Ho2024-09-30T02:11:17-04:00DeepLook Medical – a healthtech company specializing in visual enhancement technology for advanced medical imaging – announced it marked the 11th investment in Xcellerant VC Fund 1. Michael Shufeldt, MBA, Principal at Xcellerant Ventures, will join the board. DeepLook Medical’s flagship product, DL Precise, is an innovative AI-powered software that equips healthcare professionals with the tools to detect and assess suspicious lesions in dense breast tissue accurately. Read more >>

DeepLook Medical Raises $1.7M for AI-Driven Cancer Detection in Dense Breast Tissue

Antonette Ho2024-02-10T18:15:14-05:00US-based healthtech company DeepLook Medical has raised $1.7M to enhance cancer detection in dense breast tissue through advanced visual enhancement technology. The company has introduced a pioneering AI technology platform tailored for identifying suspicious masses in women with dense breasts. This innovation is significant as approximately 45% of women have dense breasts, which increases their risk of breast cancer. Traditional mammograms can miss nearly half of cancers in dense breasts, which poses a significant challenge in early cancer detection.

This Startup Can Improve Cancer Screenings, Starting With Mammograms

Antonette Ho2023-12-27T22:15:45-05:00As of March 2023, the Food and Drug Administration required that mammogram facilities start notifying patients about their breast density so that they know their risks and can act accordingly, such as pursuing another imaging option. As Marissa Fayer MBA, CEO of Deeplook Medical, adds, a post-mammogram note about breast density puts the onus around patients to decide their next steps and balance risks and costs. Deeplook Medical, in contrast, can give information beyond just breast density to help empower...

DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance

Ziad2022-11-25T14:00:29-05:00 Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool. Read more >>